Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 6,033 | $92.42 | $557,569.26 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805,378 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.885 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 12,279 | $98.78 | $1,212,978.56 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,345 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.75 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 37,721 | $97.82 | $3,689,962.52 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787,066 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.64 to $98.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 23:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 23,923 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001576280-21-000087 · wf-form4_162924136247175.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,659 Underlying: COMMON STOCK · 23,923 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 23:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 23,923 | $4.18 | $99,998.14 |
DisclosureSEC source: 0001576280-21-000087 · wf-form4_162924136247175.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired by the Reporting Person through a cash exercise of a vested Stock Option Award. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 981 | $169.12 | $165,907.31 |
DisclosureSEC source: 0001576280-21-000018 · wf-form4_161317926872283.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 470,800 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.74 to $169.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,632 | $168.35 | $948,134.25 |
DisclosureSEC source: 0001576280-21-000018 · wf-form4_161317926872283.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 471,781 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.74 to $168.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,301 | $167.47 | $1,557,661.72 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 30 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 477,413 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.74 to $167.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,764 | $166.53 | $1,126,386.60 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 29 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 486,714 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.7275 to $166.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,116 | $165.55 | $1,178,022.49 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 28 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 493,478 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.72 to $165.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 204 | $164.10 | $33,476.77 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 27 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 500,594 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.61 to $164.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 144 | $162.81 | $23,445.30 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 26 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 500,798 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.40 to $163.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,023 | $169.03 | $849,042.21 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 25 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725,422 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.74 to $169.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 50,245 | $168.37 | $8,459,655.18 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 24 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,730,445 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.74 to $168.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 49,899 | $167.47 | $8,356,515.67 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 23 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780,690 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.74 to $167.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 44,676 | $166.51 | $7,438,893.54 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 22 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830,589 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.7275 to $166.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 48,728 | $165.55 | $8,066,706.00 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 21 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,265 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.72 to $165.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,372 | $164.10 | $225,147.26 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,923,993 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.61 to $164.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,308 | $162.65 | $375,398.51 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,925,365 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.40 to $163.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 329 | $163.94 | $53,937.15 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 500,942 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.59 to $164.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 496 | $163.03 | $80,861.00 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 501,271 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.59 to $163.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,497 | $162.11 | $729,030.26 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 501,767 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.59 to $162.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 653 | $161.02 | $105,143.84 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 506,264 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.53 to $161.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 621 | $160.07 | $99,405.27 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 506,917 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.53 to $160.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 759 | $158.98 | $120,666.73 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 507,538 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.53 to $159.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 141 | $158.08 | $22,289.28 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 508,297 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.44 to $158.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 701 | $156.80 | $109,914.07 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 508,438 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.44 to $157.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 492 | $156.11 | $76,805.97 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 509,139 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.44 to $156.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,000 | $163.98 | $819,912.50 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927,673 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.59 to $164.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,292 | $162.88 | $373,311.79 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932,673 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.59 to $163.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 27,471 | $162.10 | $4,453,137.01 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,934,965 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.59 to $162.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,594 | $161.06 | $739,897.24 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,436 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.53 to $161.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,583 | $160.08 | $733,652.60 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,967,030 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.53 to $160.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,007 | $158.97 | $795,962.29 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,971,613 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.53 to $159.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 709 | $158.13 | $112,112.33 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,620 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.44 to $158.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,579 | $156.77 | $717,871.81 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,977,329 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.44 to $157.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:19 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,069 | $156.11 | $635,212.00 |
DisclosureSEC source: 0001576280-21-000017 · wf-form4_161317914559185.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,981,908 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.44 to $156.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The amount of shares beneficially owned reflects the addition of 345 shares that were previously incorrectly reported as sold on Form 4s filed on February 3, 2021 and February 5, 2021. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 26 | $164.28 | $4,271.19 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 28 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 509,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.25 to $164.285, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,064 | $163.84 | $665,851.04 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 27 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 509,657 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.24 to $164.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,813 | $162.85 | $1,272,361.11 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 26 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 513,721 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.24 to $163.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,166 | $161.95 | $512,747.31 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 25 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 521,534 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.24 to $162.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 362 | $164.27 | $59,465.05 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 24 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985,632 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.25 to $164.285, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 27,039 | $163.84 | $4,430,158.99 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 23 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985,994 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.24 to $164.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 52,325 | $162.85 | $8,521,225.67 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 22 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013,033 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.24 to $163.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 21,385 | $161.96 | $3,463,414.09 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 21 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,065,358 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.24 to $162.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 72 | $163.98 | $11,806.80 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 524,700 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.95 to $164.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,233 | $163.04 | $690,136.04 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 524,772 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.83 to $163.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,325 | $162.26 | $1,188,588.20 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 529,005 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.83 to $162.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,187 | $161.48 | $353,148.45 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 536,330 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.83 to $161.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 60 | $163.99 | $9,839.30 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,743 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.95 to $164.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.